CFML
PBE icon

COMPASS FINANCIAL MANAGEMENT LLC’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
+300
New +$24.7K ﹤0.01% 829

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
PIM
Penobscot Investment Management Boston, Massachusetts $1.46B AUM 32.32% 1-Year Est. Return
MWM
Massachusetts Wealth Management North Andover, Massachusetts $262M AUM 48.07% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's PBE Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q2 2026: 300 shares worth $26.9K. The stake represents ﹤0.01% of the portfolio and ranks #829 among its holdings.

85 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • COMPASS FINANCIAL MANAGEMENT LLC held 300 shares of Invesco Biotechnology & Genome ETF worth $26.9K as of Q2 2026.
  • Invesco Biotechnology & Genome ETF was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #829 holding.
  • 85 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.